| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9940956 | American Journal of Hypertension | 2005 | 8 Pages |
Abstract
These results suggest that PPARγ in ECs not only is an important regulator of hypertension and HR under stressed conditions mimicking those arising in type 2 diabetics, but also mediates the antihypertensive effects of rosiglitazone. These data add evidence supporting a beneficial role for PPARγ-specific ligands in the treatment of hypertension, and suggest therapeutic strategies targeting ECs may prove useful.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Christopher J. Nicol, Masahiro Adachi, Taro E. Akiyama, Frank J. Gonzalez,